Register for our free email digests:
Apotex Inc.
http://www.apotex.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apotex Inc.
ANDA Submissions Drop To Start FY 2021, Perhaps Forced Down By COVID-19
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
Apotex Loses Again On Alternate Salt Alimta In US
Apotex’ 505(b)(2) new drug application rival to Alimta will stay off the US market after the Federal Circuit found that a lower court had correctly concluded that prosecution history estoppel did not bar Lilly’s infringement claims against the Canadian firm under the doctrine of equivalents.
Perrigo Among Firms Requesting Delay In Conducting US Nitrosamine Risk Assessments
Perrigo, Pfizer want FDA to postpone its March deadline for conducting nitrosamine risk assessments. Generics executive cites “serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Executive Decisions: Hardwick Heads US Apotex, Stada Adds To German Management, Lovett Leads Nutrition21 Marketing, More
Hardwick heads Apotex in US; DSM expands cycling team support; Stada adds to Germany management; Lovett leads Nutrition21 marketing; Viatris appoints head of capital markets; and Redcon1 sponsors bodybuilder Greene, wrestler Omega.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Apobiologix
- ApoPharma, Inc.
- Apotex Australia
- Arrow Pharmaceuticals Pty Ltd.
- Arrow Remedies Private Limited
- Arrotex Australia Group Pty Ltd
- Aveva Drug Delivery Systems, Inc.